JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 57(2023) N 3 p. 550-562; DOI 10.1134/S0026893323030147 Full Text

A.A. Vasileva1,2*, S.A. Aliukas3, P.A. Selkova1,2, A.N. Arseniev1,2, V.E. Chernova2, O.S. Musharova1, E.I. Klimuk1, M.A. Khodorkovskii2, K.V. Severinov1,4**

Type II CRISPR-Cas System Nucleases: A Pipeline for Prediction and In Vitro Characterization

1Institute of Molecular Genetics, Russian Academy of Sciences, Moscow, 123182 Russia
2Peter the Great St. Petersburg Polytechnic University, St. Petersburg, 195251 Russia
3OOO Biotechnological Campus, Moscow, 117437 Russia
4Waksman Institute of Microbiology, Piscataway, NJ, 08854 United States

*daucussativus7@gmail.com
**severik@waksman.rutgers.edu
Received - 2022-11-25; Revised - 2022-12-18; Accepted - 2022-12-23

The use of CRISPR-Cas bacterial adaptive immunity system components for targeted DNA changes has opened broad prospects for programmable genome editing of higher organisms. The most widely used gene editors are based on the Cas9 effectors of the type II CRISPR-Cas systems. In complex with guide RNAs, Cas9 proteins are able to directionally introduce double-stranded breaks into DNA regions that are complementary to guide RNA sequences. Despite the wide range of characterized Cas9s, the search for new Cas9 variants remains an important task, since the available Cas9 editors have several limitations. This paper presents a workflow for the search for and subsequent characterization of new Cas9 nucleases developed in our laboratory. Detailed protocols describing the bioinformatical search, cloning, and isolation of recombinant Cas9 proteins, testing for the presence of nuclease activity in vitro, and determining the PAM sequence, which is required for recognition of DNA targets, are presented. Potential difficulties that may arise, as well as ways to overcome them, are considered.

CRISPR, Cas9, nuclease, genome editing, bioinformatics search



JMB-FOOTER RAS-JOURNALS